Cefditoren in upper and lower community-acquired respiratory tract infections

References

• MogyorosMChallenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistanceAm J Man Care20017Suppl 6163169
   Web of Science ®Google Scholar
• LlorCConsideraciones a la hora de la prescripción antibiótica en atención primariaMed Clin Monogr (Barc)200455257
   Google Scholar
• HuovinenPCarsOControl of antimicrobial resistance: time for action. The essentials of control are already well knownBMJ19983176136149727984
   PubMed Web of Science ®Google Scholar
• García-ReyCFenollAAguilarLCasalJEffect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in SpainJ Antimicrob Chemother20045446547115269198
   PubMed Web of Science ®Google Scholar
• GranizoJJAguilarLCasalJGarcía-ReyCDal-RéRBaqueroFStreptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979–1997)J Antimicrob Chemother20004676777311062196
   PubMed Web of Science ®Google Scholar
• García-ReyCAguilarLBaqueroFCasalJDal-RéRImportance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniaeJ Clin Microbiol20024015916411773111
   PubMed Web of Science ®Google Scholar
• GómezJRuiz-GómezJHernández-CardonaJLNuñezMLCanterasMValdésMAntibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a prospective study in Murcia, Spain, 1983–1992Chemotherapy1994402993037956452
   PubMed Web of Science ®Google Scholar
• GranizoJJAguilarLCasalJDal-RéRBaqueroFStreptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–1997)J Antimicrob Chemother20004695996411102415
   PubMed Web of Science ®Google Scholar
• García-ReyCAguilarLBaqueroFCasalJMartínJEPharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in SpainJ Clin Microbiol2002402959296312149359
   PubMed Web of Science ®Google Scholar
• Pérez-TralleroEGarcía-de-la-FuenteCGarcía-ReyCGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in SpainAntimicrob Agents Chemother2005491965197215855520
   PubMed Web of Science ®Google Scholar
• Gómez-LusRGranizoJJAguilarLBouzaEGutierrezAGarcía-de-LomasJIs there an ecological relationship between rates of antibiotic resistance of species of the genus Streptococcus? The Spanish Surveillance Group for Respiratory PathogensJ Clin Microbiol1999373384338610488213
   PubMed Web of Science ®Google Scholar
• RichterSSHeilmannKPBeekmannSEMacrolide-resistant Streptococcus pyogenes in the United States, 2002–2003Clin Infect Dis20054159960816080080
   PubMed Web of Science ®Google Scholar
• ChanJCChuYWChuMYCheungTKLoJYEpidemiological analysis of Streptococcus pyogenes infections in Hong KongPathology20094168168620001348
   PubMed Web of Science ®Google Scholar
• GraciaMDíazCCoronelPAntimicrobial susceptibility of Streptococcus pyogenes in Central, Eastern, and Baltic European Countries, 2005 to 2006: the cefditoren surveillance programDiagn Microbiol Infect Dis200964525619232860
   PubMed Web of Science ®Google Scholar
• Pérez-TralleroEMartín-HerreroJEMazónAAntimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996–1997 to 2006–2007)Antimicrob Agents Chemother2010542953295920439616
   PubMed Web of Science ®Google Scholar
• PrietoJCalvoAGómez-LusMLAntimicrobial resistance: a class effect?J Antimicrob Chemother200250Suppl S2712
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-S19Clinical and Laboratory Standards InstituteWayne, PA USA2009
   Google Scholar
• SahmDFBrownNPThornsberryCJonesMEAntimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspectivePostgrad Med20081203 Suppl 1162418931467
   PubMed Web of Science ®Google Scholar
• SahmDFBrownNPDraghiDCEvangelistaATYeeYCThornsberryCTracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001–2005Postgrad Med20081203 Suppl 181518931466
   PubMed Web of Science ®Google Scholar
• JansenWTVerelABeitsmaMVerhoefJMilatovicDLongitudinal European surveillance study of antibiotic resistance of Haemophilus influenzaeJ Antimicrob Chemother20065887387716891323
   PubMed Web of Science ®Google Scholar
• SevillanoDGiménezMJCercenadoEGenotypic versus phenotypic characterization, with respect to beta-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to beta-lactam resistance markersAntimicrob Agents Chemother20095326727018955529
   PubMed Web of Science ®Google Scholar
• NikiYHanakiHMatsumotoTNationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibilityJ Infect Chemother20091515616719554400
   PubMed Web of Science ®Google Scholar
• SakataHToyonagaYSatoYNationwide survey of the development of drug-resistance in the pediatric field: drug sensitivity of Haemophilus influenzae in JapanJ Infect Chemother20091540240920012732
   PubMed Web of Science ®Google Scholar
• PericMBozdoganBJacobsMRAppelbaumPCEffects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolatesAntimicrob Agents Chemother2003471017102212604536
   PubMed Web of Science ®Google Scholar
• CantónRUnalSFarrellDJAntibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients: PROTEKT years 1–5 (1999–2004)Int J Antimicrob Agents20073054655017931834
   PubMed Web of Science ®Google Scholar
• DarabiAHocquetDDowzickyMJAntimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance TrialDiagn Microbiol Infect Dis201067788620385351
   PubMed Web of Science ®Google Scholar
• Pérez-TralleroEGarcía-de-la-FuenteCGarcía-ReyCGeographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in SpainAntimicrob Agents Chemother2005491965197215855520
   PubMed Web of Science ®Google Scholar
• FenollAGranizoJJAguilarLTemporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007J Clin Microbiol2009471012102019225097
   PubMed Web of Science ®Google Scholar
• FenollAAguilarLGranizoJJHas the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?J Antimicrob Chemother2008621430143318819966
   PubMed Web of Science ®Google Scholar
• WhitneyCGFarleyMMHadlerJDecline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccineN Engl J Med20033481737174612724479
   PubMed Web of Science ®Google Scholar
• FenollAAguilarLGiménezMJSusceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccineAntimicrob Agents Chemother2010542696269820308373
   PubMed Web of Science ®Google Scholar
• FenollAAguilarLViciosoMDSerotype distribution and susceptibility of Streptococcus pneumoniae isolates from pleural fluid in the current decade in SpainAntimicrob Agents Chemother2010545387539020921314
   PubMed Web of Science ®Google Scholar
• PicazoJRuiz-ContrerasJCasado-FloresJRelations between serotypes, age and clinical presentation of invasive pneumococcal disease in Madrid after the introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendarClin Vaccine Immunol201118899421047996
   PubMedGoogle Scholar
• Pérez-TralleroEMarimónJMErcibengoaMGiménezMJCoronelPAguilarLAntimicrobial susceptibilities of amoxycillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniaeClin Microbiol Infect20071393794017617182
   PubMed Web of Science ®Google Scholar
• SorianoFCafiniFAguilarLBreakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatednessJ Antimicrob Chemother2008621234124018799472
   PubMed Web of Science ®Google Scholar
• Rodríguez-CerratoVGraciaMDel PradoGAntimicrobial susceptibility of multidrug-resistant Streptococcus pneumoniae strains with penicillin MICs of 8 to 32 mg/LDiagn Microbiol Infect Dis20106633633819939599
   PubMed Web of Science ®Google Scholar
• WellingtonKCurranMPCefditoren pivoxil: a review of its use in the treatment of bacterial infectionsDrugs2004642597261815516158
   PubMed Web of Science ®Google Scholar
• YamadaMWatanabeTMiyaraTCrystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activityAntimicrob Agents Chemother2007514550
   Web of Science ®Google Scholar
• GraciaMDíazCCoronelPAntimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005–06: results of the Cefditoren Surveillance StudyJ Antimicrob Chemother2008611180118118316820
   PubMed Web of Science ®Google Scholar
• García-de-LomasJLermaMCebriánLInfluence of Haemophilus influenzae beta-lactamase production and/or ftsI gene mutations on in vitro activity of and susceptibility rates to aminopenicillins and second- and third-generation cephalosporinsInt J Antimicrob Agents20073019019217459665
   PubMed Web of Science ®Google Scholar
• SorianoFGranizoJJFenollAAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance programJ Chemother20031510711212797384
   PubMed Web of Science ®Google Scholar
• SorianoFCoronelPGimenoMJiménezMGarcía-CorbeiraPFernández-RoblasRInoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidisEur J Clin Microbiol Infect Dis1996157617638922582
   PubMed Web of Science ®Google Scholar
• SádabaBAzanzaJRQuetglasEGPharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I studyRev Esp Quimioter200720516017530036
   PubMed Web of Science ®Google Scholar
• CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis1998261109455502
   PubMed Web of Science ®Google Scholar
• HeffelfingerJDDowellSFJorgensenJHManagement of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working GroupArch Intern Med20001601399140810826451
   PubMed Web of Science ®Google Scholar
• GranizoJJSádabaBHonoratoJMonte Carlo simulation describing the pharmacodynamic profile of cefditoren in plasma from healthy volunteersInt J Antimicrob Agents20083139639818178067
   PubMed Web of Science ®Google Scholar
• MoelleringRCEliopoulosGMPrinciples of anti-infective therapyMandellGLBennettJEDolinRMandell, Douglas, and Bennett Principles and Practice of Infectious Diseases6th edPhiladelphiaElsevier Churchill Livingstone2005242253
   Google Scholar
• CafiniFYusteJGiménezMJEnhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis modelPLoS One201058e1204120706584
   PubMed Web of Science ®Google Scholar
• SevillanoDAguilarLAlouLHigh protein binding and cidal activity against penicillin-resistant S. pneumoniae: a cefditoren in vitro pharmacodynamic simulationPLoS One200837e271718648650
   PubMed Web of Science ®Google Scholar
• KarlowskyJAJonesMEDraghiDCCritchleyIAThornsberryCSahmDFIn vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditorenDiagn Microbiol Infect Dis200242596411821173
   PubMed Web of Science ®Google Scholar
• JohnsonDMBiedenbachDJBeachMLPfallerMAJonesRNAntimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus speciesDiagn Microbiol Infect Dis2000379910510863104
   PubMed Web of Science ®Google Scholar
• JonesRNBiedenbachDJCrocoMABarrettMSIn vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniaeDiagn Microbiol Infect Dis1998315735789764398
   PubMed Web of Science ®Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios https://sinaem4.agemed.es/consaem/fichasTecnicas.do?metodo=detalleForm.
   Google Scholar
• Food and Drug AdministrationSpectracef prescribing information http://www.crtx.com/docs/spectracef.pdf.
   Google Scholar
• WeinbergerDMDaganRGivon-LaviNEpidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriageJ Infect Dis20081971511151818471062
   PubMed Web of Science ®Google Scholar
• SoininenAPursiainenHKilpiTKäyhtyHNatural development of antibodies to pneumococcal capsular polysaccharides depends on the serotype: association with pneumococcal carriage and acute otitis media in young childrenJ Infect Dis200118456957611494163
   PubMed Web of Science ®Google Scholar
• FelminghamDRobbinsMJGhoshGAn in vitro characterization of cefditoren, a new oral cephalosporinDrugs Exp Clin Res1994201271477813385
   PubMedGoogle Scholar
• GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLEfficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trialsRev Esp Quimioter200821142118443928
   PubMed Web of Science ®Google Scholar
• OzakiTNishimuraNSuzukiMFive-day oral cefditoren pivoxil versus 10-day oral amoxicillin for pediatric group A streptococcal pharyngotonsillitisJ Infect Chemother20081421321818574657
   PubMedGoogle Scholar
• KikutaHShibataMNakataSComparative study of 5-day and 10-day cefditoren pivoxil treatments for recurrent group A beta-hemolytic Streptococcus pharyngitis in childrenInt J Pediatr200986360820041005
   PubMedGoogle Scholar
• PoachanukoonOKitcharoensakkulMEfficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trialClin Ther2008301870187919014842
   PubMed Web of Science ®Google Scholar
• GranizoJJGiménezMJBarberánJCoronelPGimenoMAguilarLThe efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trialsClin Ther2006282061206917296462
   PubMed Web of Science ®Google Scholar
• CaseyJRPichicheroMEThe evidence base for cephalosporin superiority over penicillin in streptococcal pharyngitisDiagn Microbiol Infect Dis2007573 SupplS39S45
   Web of Science ®Google Scholar
• BudhaniRKStruthersJKInteraction of Streptococcus pneumoniae and Moraxella catarrhalis: investigation of the indirect pathogenic role of beta-lactamase-producing moraxellae by use of a continuous-culture biofilm systemAntimicrob Agents Chemother199842252125269756750
   PubMed Web of Science ®Google Scholar
• CaseyJRPichicheroMEMeta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adultsClin Infect Dis2004381526153415156437
   PubMed Web of Science ®Google Scholar
• SevillanoDAguilarLAlouLBeta-lactam effects on mixed cultures of common respiratory isolates as an approach to treatment effects on nasopharyngeal bacterial population dynamicsPLoS One2008312e384619052648
   PubMed Web of Science ®Google Scholar
• Alvarez-SalaJLKardosPMartínez-BeltránJCoronelPAguilarLClinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetilAntimicrob Agents Chemother2006501762176716641447
   PubMed Web of Science ®Google Scholar
• GranizoJJAguilarLGimenezMJCoronelPGimenoMPrietoJSafety profile of cefditoren. A pooled analysis of data from clinical trials in community-acquired respiratory tract infectionsRev Esp Quimioter200922576119544097
   PubMed Web of Science ®Google Scholar
• AlmiranteBCamposJCantónRPrudent use of antimicrobials: have we done the best we can? The SEIMC and REIPI statementEnferm Infecc Microbiol Clin20102848548620817357
   PubMed Web of Science ®Google Scholar
• BaqueroFGarauJPrudent use of antimicrobial agents: revisiting concepts and estimating perspectives in a global worldEnferm Infecc Microbiol Clin20102848748820846754
   PubMed Web of Science ®Google Scholar
• DanemanNLowDEMcGeerAGreenKAFismanDNAt the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumoniaClin Infect Dis2008461131113818444846
   PubMed Web of Science ®Google Scholar